阿狄科®精氨酸检测试剂盒（酶联免疫法）

【产品名称】
通用名称：阿狄科®精氨酸检测试剂盒（酶联免疫法）
英文名称：IDK® L-Arginine

【包装规格】
规格：96人份（复孔检测样本：40个）/盒
测试次数：96（40份样本一式两份）

【预期用途】
用于定量测定 EDTA 血浆中的 L-精氨酸。仅供科研使用。

【背景知识】
L-精氨酸是一种有机化合物，分子式是C₆H₁₄N₄O₂，对成人为非必需氨基酸，但体内生成速度较慢，对婴幼儿为必需氨基酸，有一定解毒作用。其大量存在于鱼精蛋白等中，亦为各种蛋白质的基本组成，存在十分广泛。

参考文献：
1.Bailey SJ, Winyard PG, Vanhatalo A, Blackwell JR, DiMenna FJ, Wilkerson DP, JonesAMAcute L-arginine supplementation reduces the O cost of moderate-intensityexercise and enhances highintensity exercise tolerance. J Appl Physiol. 2010Nov;109(5):1394-403.doi: 10.1152/japplphysiol.00503.2010.
2.Carvalho DS, Diniz MM,Haidar AA, et al. L-Arginine supplementation improvesinsulin sensitivity and beta cell function in the offspring of diabetic rats through AKTand PDX-1activation. Eur」Pharmacol. 2016;791:780-787.doi:10.1016/j.ejphar.2016.10.001.
3.Fayh APT, Krause M, Rodrigues-Krause J, et al.Effects of l-arginine supplementationon blood flow, oxidative stress status and exercise responses in young adults withuncomplicated type l diabetes.Eur J Nutr. 2013;52(3):975-983.doi:10.1007/s00394-012-0404-7.
4.Fazelian S, Hoseini M, Namazi N, et al.Effects of L- Arginine Supplementation on Antioxidant Status and Body Composition in Obese Patients with Pre-diabetes: ARandomized Controlled Clinical Trial.Adv Pharm Bull.2014;4(Suppl 1):449-454.doi:10.5681/apb.2014.066.
5.Giam B, Kuruppu S, Head G, Kaye D, Rajapakse N. Effects of Dietary lArginine onNitric Oxide Bioavailability in Obese Normotensive and Obese HypertensiveSubjects.Nutrients. 2016;8(6):364.doi:10.3390/nu8060364
6.Hoang HH, Padgham S V, Meininger CJ.L-arginine, tetrahydrobiopterin, nitric oxideanddiabetes. Curr OpinClin Nutr Metab Care. 2013;16(1):76-82.doi:10.1097/MCO.0b013e32835ad1ef.
7.Neri l, Monari F, Sgarbi L, Berardi A,Masellis G,Facchinetti F. L-argininesupplementation in women with chronic hypertension: impact on blood pressureand maternal and neonatal complications. J Matern Fetal Neonatal Med.2010Dec23(12):1456-60.doi: 10.3109/14767051003677962.
8.Piatti PM,Monti LD, Valsecchi G, et al.Long-term oral L-arginine administrationimproves peripheral and hepatic insulin sensitivity in type 2 diabetic patients.Diabetes Care.2001;24(5):875-880.doi:10.2337/diacare.24.5.875.
9.Rajapakse NW, Chong AL,Zhang W-Z, Kaye DM.Insulin-mediated activation of theL-arginine nitric oxide pathway in man, and its impairment in diabetes.PLoS One.20138(5): e61840.doi:10.1371/journal.pone.0061840.
10. Saleh Al,Abdel Maksoud SM, EI-Maraghy SA, Gad MZ.Protective effect of L-arginine in experimentally induced myocardial ischemia: comparison with aspirin. JCardiovasc Pharmacol Ther.2011 Mar;16(1):53-62.doi:10.1177/1074248410378506.
11.Schwedhelm E, Wallaschofski H, Atzler D, et al. Incidence of AllCause and Cardiovascular Mortality Predicted by Symmetric Dimethylarginine in thePopulation-Based Study of Health in Pomerania.PLoS One. 2014,9(5):e96875.doi:10.1371/journal.pone.0096875.
12.Tripathi P, Chandra M, Misra MK.Oral administration of L-arginine in patients with angina or following myocardial infarction may be protective by increasing plasmasuperoxide dismutase and total thiols with reduction in serum cholesterol andxanthine oxidase. Oxid Med Cell Longev. 2009 Sep-Oct;2(4):231-7. doi:10.4161/oxim.2.4.9233.
13.Visser M, Paulus WJ, Vermeulen MA,Richir MC, Davids M, Wisselink W, de Mol BA,van Leeuwen PA.The role of asymmetric dimethylarginine and arginine in the failingheart and its vasculature. Eur J Heart Fail. 2010 Dec;12(12):1274-81. doi:10.1093/eurjhf/hfq158.
14.Brenner T, Fleming TH, Rosenhagen C, Krauser U,Mieth M,Bruckner T, Martin E,Nawroth PP,Weigand MA，Bierhaus A，Hofer S. L-arginine and asymmetricdimethylarginine are early predictors for survival in septic patients with acute liverfailure.Mediators Inflamm.2012;2012:210454.doi:10.1155/2012/210454.
15.Brenner T, Fleming TH,Spranz D, Schemmer P,Bruckner T, Uhle F，Martin EO,Weigand MA, Hofer S.Reactive Metabolites and AGE-RAGE-Mediated Inflammationin Patients Following Liver Transplantation.Mediators Inflamm.2013;2013:501430.doi:10.1155/2013/501430.